0

Cost-effectiveness analysis of lorlatinib in patients previously treated with anaplastic lymphoma kinase inhibitors for non-small cell lung cancer in Greece

Authors:

Gourzoulidis G, Zisimopoulou O, Boubouchairopoulou N, Michailidi C, Lowry C, Tzanetakos C and Kourlaba G.

Publication type:

Conference Proceedings – Poster

Publication Name:

Virtual ISPOR Europe 2020

Citation:

Gourzoulidis G, Zisimopoulou O, Boubouchairopoulou N, Michailidi C, Lowry C, Tzanetakos C and Kourlaba G. Cost-effectiveness analysis of lorlatinib in patients previously treated with anaplastic lymphoma kinase inhibitors for non-small cell lung cancer in Greece. Virtual ISPOR Europe 2020. 16-19 November 2020. Poster PCN56.

Link to publication ⟶

⟵ Back to Search Results

An incremental effectiveness analysis of lorlatinib for the treatment of ALK-positive advanced non-small cell lung cancer that has progressed after another ALK tyrosine kinase inhibitor in Portugal
Cost-effectiveness analysis of NOVEL therapies for HER2+ metastatic breast cancer- [FAM-] trastuzumab deruxtecan versus tucatinib trastuzumab and capecitabine
By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies
By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies